ArriVent BioPharma (AVBP) News Today

ArriVent BioPharma, Inc. (NASDAQ: AVBP) is under significant pressure after its lead lung-cancer drug, firmonertinib, failed to meet the primary endpoint in the Phase 3 FURVENT trial. The setback has sharply reduced investor confidence in the company’s development pipeline and pushed the stock near its 12-month low, with trading volume substantially above average.

• Positive Sentiment: Analysts retain buy ratings despite major target cuts. HC Wainwright lowered its price target from $47 to $27, Citigroup cut its target from $40 to $20, and JonesTrading reduced its target from $45 to $22. All three firms maintained “buy” ratings, suggesting they see potential value after the selloff. These targets imply substantial upside from recent trading levels.
• Neutral Sentiment: ArriVent is reviewing its strategy for firmonertinib. Following the Phase 3 failure, the company is evaluating its plans for the drug and the broader implications for its lung-cancer program. The outcome of that review could determine whether additional development or regulatory options remain available. ArriVent reviews firmonertinib plans after Phase III setback
• Negative Sentiment: The FURVENT Phase 3 trial missed its primary endpoint. Reports described the result as a failure of ArriVent’s lead asset in late-stage lung cancer, triggering a severe selloff and raising concerns about the company’s future commercial prospects. ArriVent BioPharma Shares Plunge 58% On Phase 3 FURVENT Failure ArriVent stock tumbles after trial misses primary endpoint
• Negative Sentiment: Shareholder and fraud investigations add legal overhang. Law firms have solicited investors who suffered significant losses and announced investigations into potential securities claims involving ArriVent. These announcements do not establish wrongdoing, but they may increase reputational, legal and financial risks. SBS Law ArriVent investor investigation